Telomir Pharmaceuticals, Return On Equity vs. Shares Owned By Institutions
| TELO Stock | 4.91 0.03 0.61% |
Return On Equity | First Reported 2010-12-31 | Previous Quarter (3.80) | Current Value (3.61) | Quarterly Volatility 1.62506723 |
For Telomir Pharmaceuticals, profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Telomir Pharmaceuticals, to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Telomir Pharmaceuticals, Common utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Telomir Pharmaceuticals,'s most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Telomir Pharmaceuticals, Common over time as well as its relative position and ranking within its peers.
Telomir |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Telomir Pharmaceuticals,. If investors know Telomir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Telomir Pharmaceuticals, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.78) | Return On Assets (2.05) | Return On Equity (17.53) |
The market value of Telomir Pharmaceuticals, is measured differently than its book value, which is the value of Telomir that is recorded on the company's balance sheet. Investors also form their own opinion of Telomir Pharmaceuticals,'s value that differs from its market value or its book value, called intrinsic value, which is Telomir Pharmaceuticals,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Telomir Pharmaceuticals,'s market value can be influenced by many factors that don't directly affect Telomir Pharmaceuticals,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Telomir Pharmaceuticals,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Telomir Pharmaceuticals, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Telomir Pharmaceuticals,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Telomir Pharmaceuticals, Shares Owned By Institutions vs. Return On Equity Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Telomir Pharmaceuticals,'s current stock value. Our valuation model uses many indicators to compare Telomir Pharmaceuticals, value to that of its competitors to determine the firm's financial worth. Telomir Pharmaceuticals, Common is rated fifth in return on equity category among its peers. It also is rated fifth in shares owned by institutions category among its peers . At this time, Telomir Pharmaceuticals,'s Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Telomir Pharmaceuticals,'s earnings, one of the primary drivers of an investment's value.Telomir Shares Owned By Institutions vs. Return On Equity
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Telomir Pharmaceuticals, |
| = | -17.53 |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Telomir Pharmaceuticals, |
| = | 6.90 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Telomir Shares Owned By Institutions Comparison
Telomir Pharmaceuticals, is currently under evaluation in shares owned by institutions category among its peers.
Telomir Pharmaceuticals, Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Telomir Pharmaceuticals,, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Telomir Pharmaceuticals, will eventually generate negative long term returns. The profitability progress is the general direction of Telomir Pharmaceuticals,'s change in net profit over the period of time. It can combine multiple indicators of Telomir Pharmaceuticals,, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -49.5 K | -52 K | |
| Operating Income | -3.5 M | -3.4 M | |
| Net Loss | -11.8 M | -11.2 M | |
| Income Before Tax | -11.8 M | -11.2 M | |
| Total Other Income Expense Net | -8.2 M | -7.8 M | |
| Net Loss | -11.8 M | -11.2 M | |
| Income Tax Expense | -2.1 M | -2 M | |
| Net Interest Income | -1.5 M | -1.4 M | |
| Net Loss | (0.44) | (0.42) | |
| Income Quality | 0.30 | 0.28 |
Telomir Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Telomir Pharmaceuticals,. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Telomir Pharmaceuticals, position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Telomir Pharmaceuticals,'s important profitability drivers and their relationship over time.
Use Telomir Pharmaceuticals, in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Telomir Pharmaceuticals, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Telomir Pharmaceuticals, will appreciate offsetting losses from the drop in the long position's value.Telomir Pharmaceuticals, Pair Trading
Telomir Pharmaceuticals, Common Pair Trading Analysis
The ability to find closely correlated positions to Telomir Pharmaceuticals, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Telomir Pharmaceuticals, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Telomir Pharmaceuticals, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Telomir Pharmaceuticals, Common to buy it.
The correlation of Telomir Pharmaceuticals, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Telomir Pharmaceuticals, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Telomir Pharmaceuticals, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Telomir Pharmaceuticals, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Telomir Pharmaceuticals, position
In addition to having Telomir Pharmaceuticals, in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Most Shorted Equities Thematic Idea Now
Most Shorted Equities
Dynamically calculated list of top equities currently trending upward via a buy-out by investors. The Most Shorted Equities theme has 197 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Most Shorted Equities Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
To fully project Telomir Pharmaceuticals,'s future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Telomir Pharmaceuticals, at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Telomir Pharmaceuticals,'s income statement, its balance sheet, and the statement of cash flows.